14th ICID - Poster Abstracts - International Society for Infectious ...

When citing these abstracts please use the following reference:
Author(s) of abstract. Title of abstract [abstract]. Int J Infect Dis 2010;14S1: Abstract number.
Please note that the official publication of the International Journal of Infectious Diseases 2010, Volume 14, Supplement 1
is available electronically on http://www.sciencedirect.com
Final Abstract Number: 23.011
Session: Antibiotic Resistance Gram-Negative
Date: Wednesday, March 10, 2010
Time: 12:30-13:30
Room: Poster & Exhibition Area/Ground Level
Type: Poster Presentation
Emerging multi drug-resistant Acinetobacter in Iran: Study of 800 cases
F. Abbasi 1 , D. Yadegarynia 2 , M. Mardani 2 , B. Frasinejad 2 , T. Yaghubi 2 , S. Gholamin 2
1 Shaheed Beheshti Medical University, Tehran, Iran, Islamic Republic of, 2 Shaheed Beheshti
Medical University, tehran, Iran, Islamic Republic of
Background: Acinetobacter baumannii is a multi drug resistant organism associated with high
morbidity and mortality. It is an emerging nosocomial pathogen in many parts of the world. The
aim of the present study was to review the incidence of Acinetobacter in several hospitals in
Tehran, Iran and also to find out pattern of antibiotic resistance of Acinetobacter. We published
primary results of this study when it was consisted of 100 samples. It was accepted in 48th
Annual ICAAC/ 46th Annual IDSA congress, Oct. 2008.
Methods: In a retrospective study we detected 800 positive cultures of Acinetobacter from 800
patients in different wards of several tertiary care hospitals in Tehran, Iran. Disk diffusion method
was used to determine the resistance of isolated Acinetobacter baumannii. Antimicrobial
sensitivity to 14 available antibiotics was analyzed. The following antibiotics were tested:
cefriaxone, cefotaxime, ceftazidime, cefepime, trimethoprim-sulfamethoxazole, gentamicin,
tobramycin, amikacin, ciprofloxacine, ofloxacine, imipenem, meropenem, piperacillin-tazobactam
and tigecycline.
Results: The most frequently sites of infection were wound, respiratry tract, blood stream, and
urinary tract. The most increminated wards were burn and intensive care unit with a high
prevalence of wound infection, pneumonia and septicemia due to Acinetobacter. Acinetobacter
was isolated from wound in 58.9%, tracheal discharge 9.2%, sputum in 7.1%, urine in 6.6%,
blood in 5.8%, CSF in 3.4%, pleural fluid in 2%, tip of catheter (CV line) in 0.6% and
brochoalveolar lavage (BAL) in 0.2%.
Acinetobacter baumannii showed resistance to cefriaxone, cefotaxime, ceftazidime and cefepime
more than 90%. Resistance to gentamicin and trimethoprim-sulfamethoxazole were more than
80%. Resistance to amikacin, imipenem and ciprofloxacine were 72.7%, 70.5% and 45.7%
respectively. Tigecycline, piperacillin-tazobactam, tobramycin and ofloxacine were evaluated in
100 samples. Sensitivity to tobramycin and ofloxacine were 28.9% and 25.3% respectively.
Tigecycline and piperacillin-tazobactam were active against 100% and 74% of the strains
respectively.
Conclusion: Acinetobacter baumanii is an increasingly isolated pathogen in Iran. Prevalence of
carbapenem resistant acinetobacter is high in our study. Newer antimicrobial compound is
needed for treatment of this infection.